SEC Form 4 · accession 0001144204-16-136389
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Gill
Officer — President and CEO · Director
Period of report
Nov 22, 2016
Accepted (ET)
Nov 23, 2016 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value per share | Nov 22, 2016 | M | 100,000 | $2.20 | A | 822,244 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $2.20 | Nov 22, 2016 | M | 100,000 | D | Nov 17, 2016 | May 31, 2026 | Common Stock | 100,000 | 0 | D |